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Abstract Due to its unique pharmacodynamic properties
of dopamine partial agonist activity, and its association
with few and mild side effects, aripiprazole is a candidate
atypical antipsychotic for patients with tic disorders. This
open-label study compared the efﬁcacy and tolerability of
aripiprazole with haloperidol, a typical antipsychotic
widely used to treat patients with tic disorders. Forty-eight
children and adolescents with tic disorders were recruited
from the outpatient clinic at South Korea and treated
with aripiprazole (initial dose, 5.0 mg/d; maximum dose
20 mg/d) or haloperidol (initial dose, 0.75 mg/d; maximum
dose, 4.5 mg/d) for 8 weeks. Treatment efﬁcacy was
measured using the yale global tic severity scale (YGTSS),
and tolerability was measured using the extrapyramidal
symptom rating scale (ESRS) and an adverse effects
checklist. Total tic scores as measured by the YGTSS
decreased over time in both groups (p\0.001) with-
out any signiﬁcant differences between groups. ESRS
scores were signiﬁcantly higher in the haloperidol group
during the 4 weeks after commencement of medication
(p\0.05). These results indicate that aripiprazole may be
a promising drug in the treatment of children and adoles-
cents with tic disorders. Further controlled studies are
needed to determine the efﬁcacy and tolerability of ari-
piprazole in these patients.
Keywords Aripiprazole  Tic disorders  Tourette
disorder  Children  Adolescents  Haloperidol
Introduction
Typical antipsychotics such as haloperidol and pimozide
have been prescribed to control tic symptoms as ﬁrst-line
agent [1]. More recently, clinical experience with atypical
neuroleptics have increased owing to the efﬁcacy and the
more tolerable adverse effects relative to some classical
antipsychotics [1–11]. Some drugs such as risperidone
[7, 12], quetiapine [13], and olanzapine [4, 10, 11], how-
ever, may cause unwanted metabolic side effects, which
may worsen patient quality of life as well as general
medical health status.
Aripiprazole is another candidate atypical antipsychotic
agent for patients with tic disorders. This drug has a lower
risk of metabolic side effects than other atypical neuro-
leptics. In addition, aripiprazole has a unique pharmaco-
dynamic property, namely dopamine partial agonist
activity [14]. Because abnormalities in the brain dopamine
system may be closely related to the pathology of tic dis-
orders [15], we hypothesized that aripiprazole may have
therapeutic effects on tic manifestations. Several clinical
trials, including our previous studies, have revealed that
aripiprazole may be successful in treating patients with tic
disorders, due to its high efﬁcacy and tolerability [16–24].
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DOI 10.1007/s00787-010-0154-0No study to date, however, has compared the efﬁcacy and
tolerability of aripiprazole and typical antipsychotics in
these patients. We therefore compared the efﬁcacy and
tolerability of aripprazole with haloperidol, a typical anti-
psychotic agent widely used to treat children and adoles-
cents with tic disorders.
Methods
Participant characteristics
Forty-eight children and adolescents with tic disorders (33
males, 15 females; mean ± SD age = 10.3 ± 3.5 years;
range, 6–15 years) were recruited at an outpatient clinic at
a general hospital in Seoul, South Korea, from August
2005 to March 2007. Before determining eligibility, we
obtained informed consent and assent from both the study
subject and the child’s primary caregiver. The study pro-
tocol was approved by our local Institutional Review
Board.
Patients were deemed eligible if they had DSM-IV
diagnosis of tic disorders, as described in the Korean ver-
sion of the Kiddie-Schedule for Affective Disorders and
Schizophrenia-Present and Lifetime Version (KSADS-PL
[25]) and Total Tic scores C22 on the Korean version of
the yale global tic severity scale (YGTSS [26, 27]), cor-
responding to at least moderate tic severity. Each patient
was subsequently examined by a board-certiﬁed child
psychiatrist.
Exclusion criteria included current mood disorders,
psychotic symptoms, and anxiety disorders, except for
obsessive–compulsive disorder, the most common comor-
bid anxiety disorder in tic patients. Subjects with an
IQ B 70 on the Korean version of the Wechsler Intelli-
gence Scale for Children-Revised (WISC-R [28]) were also
excluded, as were patients with previous or current seizure
episodes, electroencephalogram (EEG) abnormalities, and
those who had used aripiprazole previously. Subjects who
had taken psychotropic medications must have been drug-
free for at least 2 weeks before study entry and had to be
devoid of any signiﬁcant medical problems.
Study design
This was an open, non-randomized, parallel-group clinical
trial. All subjects were evaluated at baseline by routine
laboratory tests, electrocardiogram (ECG), resting pulse
rate and blood pressure while sitting, height and weight
measurement, medical history, and physical and neuro-
logical examinations. Choice of treatment was based on
patient’s preference. Patients in the aripiprazole group
started at a dose of 5.0 mg/d, which was increased in
5.0–10.0 mg/d increments every 2 weeks as tolerated
[23, 24]. Doses were reduced in 2.5–5.0 mg/d steps when
intolerable side effects emerged. The maximum allowable
dose was 20 mg/d and patients were treated for 8 weeks.
Patients in the haloperidol group were started at a dose of
0.75 mg/d and increased in 1.5–3.0 mg/day increments
every 2 weeks to a maximum tolerated dose of 4.5 mg/d
[29]. Psychotropic drugs to control comorbid psychiatric
symptoms were not prescribed during the study period.
Patients were assessed every other week, with the ﬁnal
assessment 8 weeks after the start of study medications.
Measurements
The YGTSS is a semi-structured clinical interview
designed to assess current tic severity; this scale yields
three summary scores; total motor (0–25), total phonic
(0–25), and total tic (sum of motor and phonic) scores. The
YGTTS also contains an impairment scale (0–50), which
evaluates the global level of functional impairment arising
from tics [27]. Because this study was designed to compare
efﬁcacy in reducing tic symptoms, the primary outcome
measure was total tic score. The YGTSS was administered
to each subject at each visit.
Secondary outcome measures included the Clinical
Global Impressions-Improvement scale (CGI-I [30]), and
the CGI-Severity of Illness scale (CGI-S [31]). Scores of 1
(very much improved) or 2 (much improved) in the CGI-I
were regarded as positive responses. Both of these tests
were administered at every visit.
Adverseeffectsassociatedwiththesedrugswereassessed
using an in-house adverse effect checklist, which included
the most commonly encountered side effects of aripiprazole
and haloperidol, as well as general questions on health
issues,currentillnessesorinjuries,andconcomitantmedical
treatments. The Extrapyramidal Symptom (EPS) Rating
Scale (ESRS) was also used to rate the severity of Parkin-
sonism, akathisia, dystonia, and dyskinesia [32]. We mea-
suredheightandweightateveryvisit.Atthestudyendpoint,
physical and neurological examinations, laboratory tests,
and ECG assessments were repeated.
All tests were admitted by a single psychiatrist, who was
blinded to dose changes but not to the drug of choice.
Statistical analyses
We used intent-to-treat analyses, based on patients assessed
at least once after baseline. Multiple linear regression and
generalized estimation equation (GEE) regression model-
ing were used to identify medication efﬁcacy and the sig-
niﬁcance of changes in ESRS scores. Age, gender, duration
of illness, and baseline scores of each outcome were
covariates for each analysis. Fisher’s exact test and the
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123Mann–Whitney U test were used as appropriate for
between-group comparisons. All analyses were two-sided,
with statistical signiﬁcance deﬁned at an a level of 0.05.
Results
Participant characteristics
Of the 48 children and adolescents with tic disorders, 31
were prescribed aripiprazole and 17 were prescribed halo-
peridol.Twenty-sixpatients(54.1%)hadTourette’sdisorder
and 11 (21.9%) had chronic motor and vocal tic disorders.
Eighteen participants (37.5%) had other comorbid psychi-
atric disorders, the most common being attention-deﬁcit
hyperactivitydisorder(31.3%).Themeandurationofillness
was3.0 ± 2.7 yearsand18subjects(37.5%)hadahistoryof
previous medication to control tic symptoms.
Although gender ratio, total IQ, type of tic disorders,
comorbid conditions, duration of illness, and study medi-
cations did not differ between the two groups, the mean age
was signiﬁcantly higher in the aripiprazole than in the
haloperidol group (11.2 ± 3.5 years vs. 8.6 ± 2.9 years;
Z = 2.68, p\0.01). The mean dose and duration of ari-
piprazole were 10.6 ± 5.2 mg/d and 51.7 ± 12.6 d,
respectively, whereas the mean dose and duration of hal-
operidol were 1.9 ± 1.1 mg/d and 46.3 ± 15.8 d, respec-
tively (Table 1).
Efﬁcacy of aripiprazole and haloperidol: yale global tic
severity scale
At baseline and at each follow-up visit, there were no
signiﬁcant between-group differences in tic scores, indi-
cating that these two drugs were similarly efﬁcacious in
reducing tic symptoms (Table 2). After 8 weeks of
treatment, 54.3% of the aripiprazole and 63.4% of the
haloperidol group showed reductions in total tic scores.
Total tic score decreased over time in both groups (Z =
-9.60, p\0.001) (Table 2). This reduction was particu-
larly marked at the ﬁrst follow-up visit (week 2) in both
groups (p\0.001) and was sustained throughout the study
period (Fig. 1a). There were no signiﬁcant between-group
effects or interactions.
At baseline, the mean motor tic score was higher in the
haloperidol than in the aripiprazole group (20.5 ± 3.1 vs.
17.5 ± 5.3; Z =- 1.87, p = 0.06), but the difference did
not reach statistical signiﬁcance. Aripiprazole reduced
motor tic scores 54.3% and phonic tic scores 50.0%,
whereas haloperidol reduced these scores by 58.5 and
66.2%, respectively. Motor (Z =- 8.29, p\0.001) and
phonic (Z =- 5.59, p\0.001) tic scores decreased over
time in both groups (Table 2; Fig. 1b, c), but there were no
signiﬁcant between-group effects or interaction terms.
Efﬁcacy of aripiprazole and haloperidol: clinical global
impression
The CGI-S scores of both groups decreased over time
(Z =- 8.83, p\0.001) without group or interaction
effects. Twenty-two children and adolescents (71.0%) in
the aripiprazole group and ten (58.8%) in the haloperidol
group were ‘‘much improved’’ or ‘‘very much improved’’
on the CGI-I measurement after 8 weeks of medication.
Dropout rate
Although 25 children and adolescents in the aripiprazole
group (80.6%) experienced one or more unwanted side
effects, only ﬁve (16.1%) patients inthis group discontinued
Table 1 Demographic and
clinical characteristics of the 48
children and adolescents with
tic disorders
a p\0.01 by the Mann–
Whitney U Test
IQ intelligence quotient
Aripiprazole group
(n = 31)
Haloperidol group
(n = 17)
Male, n (%) 22 (71.0) 11 (64.7)
Age mean
a (SD), years 11.2 (3.5) (range: 6–18) 8.6 (2.9) (range: 6–16)
Total IQ 108.2 ± 12.4 105.5 ± 9.1
Type of tic disorders
Tourette’s disorder, n (%) 19 (61.3) 7 (41.2)
Chronic motor and vocal tic disorder, n (%) 7 (22.6) 4 (23.5)
Transient tic disorder, n (%) 5 (16.1) 6 (35.3)
Comorbidities
Attention deﬁcit hyperactivity disorder, n (%) 9 (29.0) 6 (35.3)
Oppositional deﬁant disorder, n (%) 2 (6.5) 0 (0)
Obsessive compulsive disorder, n (%) 3 (9.7) 0 (0)
Duration of tic disorders mean (SD), years 3.4 (2.9) 2.3 (2.3)
Dose/day mean (SD), mg 10.6 (5.2) (range: 2.5–20.0) 1.9 (1.1) (range: 0.75–4.5)
Duration of study medication mean (SD), days 51.7 (12.6) (range: 14–60) 46.3 (15.8) (range: 15–61)
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123medication prematurely owing to intolerability. In contrast,
all 17 subjects in the haloperidol group experienced unex-
pected side effects and 6 (35.3%) were not able to continue
medication owing to unbearable adverse events. Although
frequencies of side effects between two groups during study
period were not different (v
2 = 2.08, p = 0.15), rates of
drug discontinuation were lower in the aripiprazole group
relative to the haloperidol group (v
2 = 7.17, p = 0.007).
The major intolerable side effects included nausea (2
patients), headache (2 patients) and sedation (1 patient) in
the aripiprazole group, and sedation (4 patients) and head-
ache (2 patients) in the haloperidol group.
Extrapyramidal symptom rating scale
The total ESRS score at study endpoint was higher in the
haloperidol than in the aripiprazole group. There were
interaction effects between groups and a time effect of the
total ESRS score (Z =- 2.17, p = 0.03). Total ESRS
scores did not change signiﬁcantly in the aripiprazole
group between 2 and 4 weeks (1.1 ± 1.7 and 1.1 ± 1.8,
respectively), but increased signiﬁcantly in the haloperidol
group between 2 and 4 weeks (1.4 ± 2.1 and 2.8 ± 2.6,
respectively); these interaction effects were statistically
signiﬁcant (Z =- 2.083, p = 0.037) (Fig. 2). In addition,
the subscale scores for Parkinsonism, akathisia and, dys-
tonia were higher in the haloperidol group at 8 weeks. The
Parkinsonism subscale of the ESRS showed an interaction
effect between group and time Z =- 2.06, p = 0.04). No
subjects experienced dyskinesia in this study (Table 3).
General adverse events
The most common side effects of aripiprazole were hyper-
somnia (58.1%), nausea/vomiting (29.0%), EPS (19.4%),
and headache (16.1%), whereas the most common side
effects of haloperidol included hypersomnia (82.4%),
headache (58.8%), EPS (41.2%), nausea/vomiting (23.5%),
gastrointestinal disturbances (11.8%), emotional hypersen-
sitivity (11.8%), dizziness (11.8%), and chest discomfort
(11.8%) (Table 4). Hypersomnia (v
2 = 4.17, p = 0.04),
EPS (v
2 = 7.84, p = 0.005), and headache (v
2 = 24.34,
Table 2 Efﬁcacy of aripiprazole and haloperidol in the treatment of tic disorders
Outcome measures Aripiprazole group
(n = 31)
Haloperidol group
(n = 17)
Statistical value
a
Baseline 8 weeks Baseline 8 weeks Group effect Time effect Group 9 time
Interaction effect
zp zp z p
YGTSS mean (SD)
Motor tic scores 17.5 (5.3) 8.0 (4.4) 20.5 (3.1) 8.5 (6.7) -1.21 0.227 -8.29 \0.001 0.61 0.540
Phonic tic scores 9.0 (6.7) 4.5 (4.6) 7.1 (8.3) 2.4 (4.3) 0.99 0.320 -5.59 \0.001 1.13 0.258
Total tic scores 26.5 (4.9) 12.1 (6.4) 27.6 (7.3) 10.1 (7.5) -0.61 0.543 -9.60 \0.001 1.28 0.201
CGI-I, n (%)
b
Very much improved – 9 (34.6) – 5 (45.5) – – – –
Much improved – 13 (50.0) – 5 (45.5)
Minimally improved – 3 (16.7) – 0 (0)
No change – 1 (3.8) – 1 (9.1)
Minimally aggravated – 0 – 0
Much aggravated – 0 – 0
CGI-S, n (%)
Normal, not Ill 0 2 (7.7) 0 1 (9.1) -0.94 0.35 -8.83 \0.001 0.69 0.490
Minimally ill 0 8 (30.7) 0 6 (54.5)
Mildly ill 0 10 (38.5) 0 3 (27.3)
Moderately ill 4 (12.9) 3 (11.5) 1 (20.0) 0
Markedly ill 12 (38.7) 3 (11.5) 7 (36.9) 0
Severely ill 15 (48.4) 0 9 (37.5) 1 (9.1)
Extremely severely ill 0 0 0 0
a To examine the group and time effects for each outcome variable, generalized estimation equation (GEE) modeling was adopted, with age,
gender, duration of illness, and baseline scores for each outcome variable included as covariates
b Calculating patients who dropped-out
YGTSS yale global tic severity scale, CGI-I clinical global impression-improvement, CGI-S clinical global impression-severity of illness
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123p\0.001) were observed less frequently in the aripiprazole
group. All laboratory results before, during and after treat-
ment were within normal limits. Any abnormalities in the
results of the ECGs including QTc changes were observed
before and after treatment. Between baseline and 8 weeks,
the mean body weight of the subjects in the aripiprazole
and haloperidol groups increased 0.16 kg/week and
0.21 kg/week,respectively,buttheseincreasesdidnotdiffer
between the two groups (Mann–Whitney U test, Z = 0.291,
p = 0.771).
Discussion
To our knowledge, this study is the ﬁrst to directly
compare the efﬁcacy and tolerability of aripiprazole and
haloperidol in the treatment of children and adolescents
with tic disorders. We found that aripiprazole was as
effective as haloperidol in reducing tic symptoms, as well
as being better tolerated. The mean dose of aripiprazole
used in this study, 10.6 mg/d, was similar to that used in
our previous studies in which children and adolescents
with tic disorders were treated with aripiprazole [16, 23,
24], and to doses used in previous studies of youths with
developmental disabilities [33–35], delusional disorder
[36], and bipolar disorders [37]. In contrast, higher doses
of aripiprazole have been used to treat children and ado-
lescents with bipolar disorders [38, 39], catatonia [40],
and generalized anxiety disorder [41], as well as in psy-
chiatric inpatients [42]. The aripiprazole dose used in this
study was lower than that used in adults with Tourette
disorder [21, 43–45].
Although various atypical antipsychotics are widely used
to treat tic disorders, they had weaker efﬁcacy than typical
neuroleptics such as haloperidol and pimozide, which can
decrease ticsymptomsbymorethan60%[29].Eventheﬁrst
atypicalantipsychotic,clozapine,wasnotabletosufﬁciently
Fig. 1 a Percentage changes in total tic scores over time in the
aripiprazole and haloperidol treatment groups. b Percentage changes
in motor tic scores over time in the aripiprazole and haloperidol
treatment groups. c Percentage changes in phonic tic scores over time
in the aripiprazole and haloperidol treatment groups The error bars
refer to standard deviation
Fig. 2 Changes in ESRS scores over time in the aripiprazole and
haloperidol treatment groups. Abbreviations ESRS extrapyramidal
symptom rating scale. The error bars refer to standard deviation
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siderable efﬁcacy, its adverse effects, such as weight gain
and sedation, limits its use for tic control [4, 10]. Uses of
quetiapine have been reported in several case reports
[12, 46–49] and open-label trials [13, 49] to decrease tic
symptoms. However, in two open-label trials testing que-
tiapine as an anti-tic drug in children and adolescents with
Tourette disorder, its efﬁcacy and tolerability were ques-
tionable. Risperidone is one of the most widely used and
best-studied atypical antipsychotics in the treatment of tic
symptoms. Although relatively safe and effective in tic
reduction, risperidone diminishes tic symptoms by less than
36%[3,6–9,50,51].Adouble-blind,randomizedtrialonthe
efﬁcacy of ziprasidone in reducing tic symptoms showed
that it reduced tic symptoms by 35%, although side effects,
most of which were tolerable, developed in more than 80%
of patients [52].
Aripiprazole may be more potent than other atypical
antipsychotics, reducing tic symptoms by 40–53% [23, 24].
Aripiprazole was also found to be effective in treating
antipsychotic-resistant patients with Tourette disorder [19,
21]. In the current study, 15 subjects (48.4%) in the ari-
piprazole group and 3 (17.6%) in the haloperidol group had
histories of previous ineffective treatment with antipsy-
chotic medication; nevertheless, the efﬁcacy of aripipraz-
ole was equivalent to that of haloperidol, suggesting that
aripiprazole may be a drug of choice for drug-resistant tic
patients, although further conﬁrmation is required.
In our previous report, aripiprazole was effective at its
initial dose, 5 mg, with 62.0% of the total reduction in
Total Tic Score attained within 2 weeks after the start of
treatment [24]. Although we found that tic severity in the
aripiprazole group diminished almost linearly from 2 to
8 weeks, the reduction during the ﬁrst 2 weeks, during
treatment with the initial dose of 5 mg/day, accounted for
60.0% of the total reduction in Total Tic Score, observed in
this study. This indicates that aripiprazole may be useful in
the treatment of children and adolescents with tic disorders,
especially those with unbearable or strongly dysfunctional
tic symptoms who need prompt symptom improvement.
More than 80% of youths taking aripiprazole experi-
enced one or more unwanted side effects. This high inci-
dence may have been due to the starting dose of 5 mg,
which may be too high in children and adolescents with tic
disorders. Nineteen subjects (61.3%) in the aripiprazole
group experienced side effects after their ﬁrst dose, with
the side effects experienced by four patients (21.1%) dis-
appearing spontaneously without any management or dose
reduction at the next visit. Further clinical studies using
lower initial doses of aripiprazole are required to conﬁrm
this possibility.
Table 3 Extrapyramidal symptom rating scale scores at study endpoint in the aripiprazole and haloperidol groups
Extrapyramidal symptom rating
scale scores mean (SD)
Aripiprazole
group
Haloperidol
group
Statistical value
a
Group effect Time effect Group 9 time interaction effect
zp zp z p
Parkinsonism 0.58 (1.06) 1.91 (1.92) -0.10 0.92 2.33 0.02 -2.06 0.04
Akathisia 0.04 (0.20) 0.36 (0.67) 0.59 0.56 1.66 0.10 -1.76 0.08
Dystonia 0.04 (0.20) 0.36 (0.67) -0.67 0.50 -0.05 0.96 -0.44 0.66
Dyskinesia 0.00 (0.00) 0.00 (0.00)
Total 0.68 (1.25) 2.64 (2.77) -0.00 1.00 2.17 0.03 -2.17 0.03
a Group and time effects on the adverse effect outcome variables were evaluated using generalized estimation equation (GEE) modeling, with
age, gender, duration of illness, and baseline scores for each outcome variable included as covariates
Table 4 Adverse effects of aripiprazole and haloperidol in the cur-
rent study
n (%)
Adverse events Aripiprazole
(n = 31)
Haloperidol
(n = 17)
Hypersomnia 18 (58.1) 14 (82.3)
Nausea/vomiting 9 (29.0) 4 (23.5)
Extrapyramidal symptoms 6 (19.4) 7 (41.2)
Headache 5 (16.1) 10 (58.8)
GI disturbances 2 (6.5) 2 (11.8)
Dry mouth 2 (6.5) 2 (11.8)
Emotional hypersensitivity 1 (3.2) 2 (11.8)
Dizziness 1 (3.2) 2 (11.8)
Chest discomfort 1 (3.2) 2 (11.8)
Anorexia 1 (3.2) 2 (11.8)
Nocturia 1 (3.2) 1 (5.9)
Increased appetite 1 (3.2) 1 (5.9)
Insomnia 1 (3.2) 2 (11.8)
Nightmare 1 (3.2) 1 (5.9)
Polydipsia 1 (3.2) 0
Blurred vision 1 (3.2) 0
Joint pain 0 2 (11.8)
Febrile sense 0 1 (5.9)
School refusal 0 1 (5.9)
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123In addition to the higher dropout rate seen in the halo-
peridol group, the rate of EPS during the 4 weeks after
starting treatment was higher in the haloperidol than in the
aripiprazole group. This may be associated with differences
inreceptorproﬁlesofthetwodrugs.Haloperidolhasastrong
antagonistic afﬁnity to dopamine 2 receptors in the nigro-
striatal dopamine pathway, causing EPS [53], whereas ari-
piprazole has partial agonistic activity at the postsynaptic
dopamine 2 receptors, reducing EPS development [14].
Aripiprazole may be a more ideal anti-tic drug owing to
its unique pharmacodynamic proﬁle, including both
antagonistic and agonistic dopamine activities, depending
on the environment of the local dopamine system [14, 54].
This activity is strongly associated with the pathological
mechanism of tic disorders. Dopamine receptor hypersen-
sitivity may be an underlying pathology of tic disorders
[15]. Although several studies have conﬁrmed the super-
sensitivity of the dopamine system in tic disorders, these
studies did not consider the anti-dopaminergic drug effects
[55–57], and several neuroimaging studies assessing
inﬂuences of drugs on the dopamine system have yielded
conﬂicting results [58–60]. Signiﬁcantly, pergolide, a typ-
ical dopamine agonist, reduced tic symptoms in two pre-
vious randomized, controlled clinical studies [61, 62].
Thus, an imbalance in dopamine systems may be a pivotal
cause of tic disorders. The stabilizing action of aripiprazole
in an environment of unbalanced dopamine status, there-
fore, as in tic-affected brain areas, may be more ideal in
abating tic symptoms.
Apart from acting as a partial dopamine agonist, ari-
piprazole has serotonin 2A antagonistic properties, which
may also facilitate its ability to stabilize the dopamine
system by increasing dopamine release [63]. The serotonin
2A receptor has been associated with tic symptoms, both in
animals [64] and humans [65]. In addition, the partial
agonistic actions of aripiprazole at the serotonin 1A
receptor might improve tic symptoms by decreasing anxi-
ety [66], which occurs frequently in patients with tic dis-
orders and has been associated with tic aggravation [1].
Moreover, the partial agonistic activities of aripiprazole on
the dopamine 3 and 4 receptors may be correlated with the
effects of this drug on tic disorders, as shown both clini-
cally [61, 62] and genetically [67–69].
Although our ﬁndings indicate that aripiprazole has
equivalentefﬁcacybuthighertolerabilitythanhaloperidolin
children and adolescents with tic disorders, our study had
several limitations, including the small sample size, open-
label approach, and short-term nature of the study. Thus, we
cannot conﬁrm the tolerability and long-term efﬁcacy of
aripiprazole in these patients. In addition, because the
patients chose aripiprazole or haloperidol, it could result in
differences such as age and baseline scores among the
groups of patients. Double-blind, placebo-controlled, and
randomized trials should be performed to overcome these
limitations and determine whether aripiprazole improves tic
symptomsorifourﬁndingsreﬂectthenaturalprogressionof
tic disorders.
Conclusions
Our ﬁndings indicate that aripiprazole may be effective and
tolerable in the treatment of children and adolescents with
tic disorders. Additional controlled studies are needed to
determine the efﬁcacy and tolerability of aripiprazole in
patients with tic disorders.
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